Se hai scelto di non accettare i cookie di profilazione e tracciamento, puoi aderire all’abbonamento "Consentless" a un costo molto accessibile, oppure scegliere un altro abbonamento per accedere ad ANSA.it.

Ti invitiamo a leggere le Condizioni Generali di Servizio, la Cookie Policy e l'Informativa Privacy.

Puoi leggere tutti i titoli di ANSA.it
e 10 contenuti ogni 30 giorni
a €16,99/anno

  • Servizio equivalente a quello accessibile prestando il consenso ai cookie di profilazione pubblicitaria e tracciamento
  • Durata annuale (senza rinnovo automatico)
  • Un pop-up ti avvertirà che hai raggiunto i contenuti consentiti in 30 giorni (potrai continuare a vedere tutti i titoli del sito, ma per aprire altri contenuti dovrai attendere il successivo periodo di 30 giorni)
  • Pubblicità presente ma non profilata o gestibile mediante il pannello delle preferenze
  • Iscrizione alle Newsletter tematiche curate dalle redazioni ANSA.


Per accedere senza limiti a tutti i contenuti di ANSA.it

Scegli il piano di abbonamento più adatto alle tue esigenze.

Stem cell injections for ALS safe - paper

Stem cell injections for ALS safe - paper

Italian doctors set to move to second stage of treatment trials

Rome, 28 May 2019, 14:18

Redazione ANSA

ANSACheck

Tests by Italian doctors in which human neural stem cells were injected into sufferers of amyotrophic lateral sclerosis (ALS) show the procedure is safe, according to a paper published in the Stem Cells Translational Medicine journal. As a result the team is set to move to the second stage of trials on the procedure.
    The first stage of tests was conducted between 2012 and 2015 by Angelo Vescovi and Letizia Mazzini at the hospitals and clinics in Novara, Terni, Padua and San Giovanni Rotondo.
    The paper said that human neural stem cell (hNSC) lines were injected into gray matter tracts of the lumbar or cervical spinal cord of 18 patients. For up to 60 months after surgery, none of the patients manifested severe adverse effects or increased disease progression because of the treatment, it said. Eleven of the patients died, and two underwent tracheotomy "as a result of the natural history of the disease". "Our results show that transplantation of hNSC is a safe procedure that causes no major deleterious effects over the short or long term," the paper said.
    "Given the potential therapeutic effects of the hNSCs, our observations support undertaking future phase II clinical studies in which increased cell dosages are studied in larger cohorts of patients".
   

ALL RIGHTS RESERVED © Copyright ANSA

Not to be missed

Share

Or use

ANSA Corporate

If it is news,
it is an ANSA.

We have been collecting, publishing and distributing journalistic information since 1945 with offices in Italy and around the world. Learn more about our services.